

Alan I So

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/700902/publications.pdf>

Version: 2024-02-01

34
papers

1,103
citations

471061

17
h-index

395343

33
g-index

34
all docs

34
docs citations

34
times ranked

1713
citing authors

#	ARTICLE	IF	CITATIONS
1	Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance. <i>Journal of Clinical Oncology</i> , 2015, 33, 51-57.	0.8	268
2	Mechanisms of the development of androgen independence in prostate cancer. <i>World Journal of Urology</i> , 2005, 23, 1-9.	1.2	137
3	Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1837-1849.	1.9	83
4	Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6944-6954.	3.2	71
5	A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 215-220.	1.2	71
6	GLI2 Knockdown Using an Antisense Oligonucleotide Induces Apoptosis and Chemosensitizes Cells to Paclitaxel in Androgen-Independent Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 5769-5777.	3.2	62
7	Androgens and prostate cancer. <i>World Journal of Urology</i> , 2003, 21, 325-337.	1.2	40
8	The Role of Stress Proteins in Prostate Cancer. <i>Current Genomics</i> , 2007, 8, 252-261.	0.7	40
9	Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2402-2411.	1.9	38
10	Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1024-1034.	1.9	27
11	The impact of time to metastasis on overall survival in patients with prostate cancer. <i>World Journal of Urology</i> , 2018, 36, 1039-1046.	1.2	27
12	Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: Results from a Canadian multicenter collaboration. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 441-448.	0.8	26
13	Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML). <i>Urology</i> , 2016, 89, 19-26.	0.5	23
14	Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 721-726.	0.8	21
15	Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 33.	3.5	19
16	Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma. <i>Neoplasia</i> , 2015, 17, 805-816.	2.3	17
17	Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naïve and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 14, 17-23.	0.3	17
18	Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 2026.	1.6	16

#	ARTICLE	IF	CITATIONS
19	Antisense oligonucleotide therapy in the management of bladder cancer. <i>Current Opinion in Urology</i> , 2005, 15, 320-327.	0.9	15
20	A A Canadian consensus forum on the management of patients with advanced prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 14, E137-E149.	0.3	15
21	Structured assessment and followup for patients with hereditary kidney tumour syndromes. <i>Canadian Urological Association Journal</i> , 2016, 10, 214.	0.3	12
22	Inhibition of GLI2 with antisense oligonucleotides: A potential therapy for the treatment of bladder cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 20634-20647.	2.0	10
23	Canadian Urological Association guideline: Management of small renal masses – Full-text. <i>Canadian Urological Association Journal</i> , 2021, 16, E61-75.	0.3	10
24	Prostate specific antigen: an updated review. <i>Canadian Journal of Urology</i> , 2003, 10, 2040-50.	0.0	10
25	Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study. <i>Prostate</i> , 2017, 77, 1356-1365.	1.2	7
26	Defining postoperative ileus and associated risk factors in patients undergoing radical cystectomy with an Enhanced Recovery After Surgery (ERAS) program. <i>Canadian Urological Association Journal</i> , 2020, 15, 33-39.	0.3	5
27	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 576.e11-576.e16.	0.8	3
28	Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. <i>Canadian Urological Association Journal</i> , 2020, 15, E90-E96.	0.3	3
29	Metastatic Renal Cell Carcinoma to the Testis: A Clinicopathologic Analysis of Five Cases. <i>Case Reports in Pathology</i> , 2020, 2020, 1-6.	0.2	3
30	Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, 353-358.	0.3	2
31	The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib. <i>Oncotarget</i> , 2018, 9, 22631-22641.	0.8	2
32	Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model. <i>American Journal of Clinical and Experimental Urology</i> , 2018, 6, 245-259.	0.4	1
33	Canadian Urological Association guideline: Management of small renal masses – Summary of recommendations. <i>Canadian Urological Association Journal</i> , 2021, 16, 24-5.	0.3	1
34	Real-world management of metastatic castration-resistant prostate cancer (mCRPC): A national multicenter cohort study. <i>Journal of Clinical Oncology</i> , 2022, 40, 252-252.	0.8	1